Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genzyme Plans Phase III With Oral Gaucher Drug Next Year

This article was originally published in The Pink Sheet Daily

Executive Summary

Biotech provides an update on key projects during R&D day for investors.

You may also be interested in...



Pending Approvals Hold Major Implications For Myozyme Growth

Genzyme reports increasing sales for Pompe disease drug, but upcoming EU and FDA decisions could spur or stifle product’s growth.

Pending Approvals Hold Major Implications For Myozyme Growth

Genzyme reports increasing sales for Pompe disease drug, but upcoming EU and FDA decisions could spur or stifle product’s growth.

PTC Taps Genzyme’s Global Reach, Pocketbook In Ultra-orphan Licensing Deal

PTC124 offers new approach for treating lysosomal storage disorders central to Genzyme’s success, as well as other genetic diseases.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067872

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel